Microbiome Therapeutics and Recurrent Clostridioides difficile: Where Do We Go From Here?

In a randomized, placebo-controlled phase 3 trial of RBX2660 for the treatment of recurrent CDI, what was the rate of treatment success at 8 weeks post-treatment?

In a randomized, placebo-controlled phase 3 trial of SER-109 for the treatment of recurrent CDI, what was the overall rate of recurrence in patients treated with SER-109 through week 8?

Disruption of the healthy gut microbiota (dysbiosis) can result in disease-causing C difficile infection through which of the following mechanisms?

A 60-year-old woman presents with a 3-day history of watery diarrhea, abdominal pain, and fever. Two months prior, she presented with similar symptoms. A polymerase chain reaction (PCR) assay was positive for C difficile, and she was treated with oral vancomycin 125 mg 4 times daily for 10 days. This was her first episode of C difficile infection. You perform another PCR assay, which again comes back positive for C difficile. 

Based on clinical guidelines issued by the American College of Gastroenterology (ACG), what would be the most appropriate treatment for this patient?